Piet Ost
Ghent University
CancerInternal medicineRadiologyUrologySurgeryOncologyProstateBiochemical recurrenceAndrogen deprivation therapyMetastasisDiseaseProstatectomyMEDLINEProstate cancerLymph nodeToxicityCancer researchRadiation therapyClinical trialMedicine
349Publications
41H-index
5,818Citations
Publications 286
Newest
Abstract null Background null Radiotherapy to the prostate (RTp) prolongs survival for patients with low-volume, newly diagnosed metastatic prostate cancer (ndmPC). null Objective null to evaluate whether cytoreductive radical prostatectomy (cRP) is equally beneficial as RTp in low-volume ndmPC. null Design, setting, and participants null A multicenter prospective registry was established in 2014 to observe patients with ndmPC. Eligible patients were offered cRP or RTp. For this study we selecte...
Source
#1Pirus Ghadjar (University of Bern)H-Index: 29
#2Stefanie HayozH-Index: 12
Last. Ludwig Plasswilm (University of Bern)H-Index: 15
view all 0 authors...
Abstract null null Background null Salvage radiotherapy (SRT) is utilized for biochemical progression of prostate cancer after radical prostatectomy (RP). null null null Objective null To report the outcomes of the SAKK 09/10 trial comparing conventional and dose-intensified SRT. null null null Design, setting, and participants null SAKK 09/10 was a randomized, multicenter, phase 3 trial that recruited men with biochemical progression after RP. null null null Intervention null Patients were rand...
1 CitationsSource
#1Annabel Meireson (UGent: Ghent University)
#2Simon J. Tavernier (Ghent University Hospital)H-Index: 1
Last. Lieve Brochez (UGent: Ghent University)H-Index: 10
view all 17 authors...
(1) Background: Blockade of the PD-1/PD-L1 pathway has revolutionized the oncology field in the last decade. However, the proportion of patients experiencing a durable response is still limited. In the current study, we performed an extensive immune monitoring in patients with stage III/IV melanoma and stage IV UC who received anti-PD-1 immunotherapy with SBRT. (2) Methods: In total 145 blood samples from 38 patients, collected at fixed time points before and during treatment, were phenotyped vi...
Source
#1Mathieu Spaas (Ghent University Hospital)H-Index: 1
#2Nora Sundahl (Ghent University Hospital)H-Index: 12
Last. Piet Ost (UGent: Ghent University)H-Index: 41
view all 17 authors...
BACKGROUND While the introduction of checkpoint inhibitors (CPIs) as standard of care treatment for various tumor types has led to considerable improvements in clinical outcome, the majority of patients still fail to respond. Preclinical data suggest that stereotactic body radiotherapy (SBRT) could work synergistically with CPIs by acting as an in situ cancer vaccine, thus potentially increasing response rates and prolonging disease control. Though SBRT administered concurrently with CPIs has be...
Source
#1Nora Sundahl (Ghent University Hospital)H-Index: 12
#2Silke GillessenH-Index: 58
Last. Piet Ost (Ghent University Hospital)H-Index: 41
view all 4 authors...
Even though prostate-specific membrane antigen (PSMA)-positron emission tomography (PET)-computed tomography (CT) is more accurate than conventional imaging in prostate cancer patients, its impact on patient-relevant outcomes is unknown. We argue that more evidence is required before using PSMA-PET-CT as the standard of care for staging.
3 CitationsSource
#2Giulia MarvasoH-Index: 14
Last. Piet OstH-Index: 41
view all 36 authors...
Abstract Background and purpose Between 30% and 47% of patients treated with definitive radiotherapy (RT) for prostate cancer are at risk of intraprostatic recurrence during follow-up. Re-irradiation with stereotactic body RT (SBRT) is emerging as a feasible and safe therapeutic option. However, no consensus or guidelines exist on this topic. The purpose of this ESTRO ACROP project is to investigate expert opinion on salvage SBRT for intraprostatic relapse after RT. Materials and Methods A 40-it...
Source
#1Charlien Berghen (Katholieke Universiteit Leuven)H-Index: 6
#2Steven Joniau (Katholieke Universiteit Leuven)H-Index: 73
Last. Gert De Meerleer (Katholieke Universiteit Leuven)H-Index: 36
view all 9 authors...
Abstract In metastatic castration-refractory prostate cancer (mCRPC), state-of-the-art treatment consists of androgen biosynthesis inhibition (abiraterone), inhibition of the androgen receptor (enzalutamide), chemotherapy, or radium-223 in combination with androgen deprivation therapy (ADT). A subgroup of these patients show oligoprogression, with the progression of only a limited number of metastatic spots, while all other metastases remain controlled by ongoing systemic therapy. In a bi-instit...
13 CitationsSource
#1Alberto Martini (UniSR: Vita-Salute San Raffaele University)H-Index: 27
#2Nicola Fossati (UniSR: Vita-Salute San Raffaele University)H-Index: 36
Last. Alberto Briganti (UniSR: Vita-Salute San Raffaele University)H-Index: 96
view all 25 authors...
Abstract Intermediate clinical endpoints (ICEs) might aid in trial design and potentially expedite study results. However, little is known about the most informative ICE for patients receiving salvage radiation therapy (sRT) after radical prostatectomy. To investigate the most informative ICE for patients receiving sRT, we used a multi-institutional database encompassing patients treated at eight tertiary centers. Overall, 1301 men with node-negative disease who had not received any form of andr...
Source
#1Bram De Laere (KI: Karolinska Institutet)H-Index: 10
#2Alessio Crippa (KI: Karolinska Institutet)H-Index: 16
Last. ProBIO InvestigatorsH-Index: 1
view all 11 authors...
Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease, characterized by common and rare driver gene alterations that provide a selective growth advantage for progressing tumour cells. We hypothesized that the number of distinct gene driver alteration-affected pathways or gene classes was associated with poor prognosis in patients initiating androgen receptor signalling inhibitors (ARSi). We performed a post hoc analysis of an amalgamated baseline circulating tumour D...
Source
#1Mathieu Spaas (Ghent University Hospital)H-Index: 1
Last. Piet OstH-Index: 41
view all 5 authors...
ABSTRACT Radiation myositis is an infrequent late adverse effect of radiotherapy (RT), more commonly seen after hypofractionated regimens. We present the case of a 52-year-old woman with oligorecurrent metastatic melanoma who, several months after receiving local hypofractionated RT, developed a painful swelling at the irradiated site. As an integral part of routine oncologic follow-up, 18F-FDG PET/CT allowed accurate visualization of the affected region and when matched with RT treatment plans ...
Source